[Federal Register Volume 76, Number 98 (Friday, May 20, 2011)]
[Notices]
[Page 29289]
[FR Doc No: 2011-12431]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

[Summary Notice No. PE-2011-21]

Petition for Exemption; Summary of Petition Received

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of petition for exemption received.

-----------------------------------------------------------------------

SUMMARY: This notice contains a summary of a petition seeking relief
from specified requirements of 14 CFR. The purpose of this notice is to
improve the public's awareness of, and participation in, this aspect of
FAA's regulatory activities. Neither publication of this notice nor the
inclusion or omission of information in the summary is intended to
affect the legal status of the petition or its final disposition.

DATES: Comments on this petition must identify the petition docket
number involved and must be received on or before May 30, 2011.

ADDRESSES: You may send comments identified by Docket Number FAA-2011-
0505 using any of the following methods:
     Government-wide rulemaking Web site: Go to http://www.regulations.gov and follow the instructions for sending your
comments electronically.
     Mail: Send comments to the Docket Management Facility;
U.S. Department of Transportation, 1200 New Jersey Avenue, SE., West
Building Ground Floor, Room W12-140, Washington, DC 20590.
     Fax: Fax comments to the Docket Management Facility at
202-493-2251.
     Hand Delivery: Bring comments to the Docket Management
Facility in Room W12-140 of the West Building Ground Floor at 1200 New
Jersey Avenue, SE., Washington, DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal holidays.
    Privacy: We will post all comments we receive, without change, to
http://www.regulations.gov, including any personal information you
provide. Using the search function of our docket Web site, anyone can
find and read the comments received into any of our dockets, including
the name of the individual sending the comment (or signing the comment
for an association, business, labor union, etc.). You may review DOT's
complete Privacy Act Statement in the Federal Register published on
April 11, 2000 (65 FR 19477-78).
    Docket: To read background documents or comments received, go to
http://www.regulations.gov at any time or to the Docket Management
Facility in Room W12-140 of the West Building Ground Floor at 1200 New
Jersey Avenue, SE., Washington, DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: David Staples<PHONE_NUMBER>, Keira
Jones<PHONE_NUMBER>, or Tyneka Thomas<PHONE_NUMBER>, Office of
Rulemaking, Federal Aviation Administration, 800 Independence Avenue,
SW., Washington, DC 20591.
    This notice is published pursuant to 14 CFR 11.85.

    Issued in Washington, DC on May 16, 2011.
Dennis R. Pratte,
Acting Director, Office of Rulemaking.

Petition For Exemption

    Docket No.: FAA-2011-0505.
    Petitioner: International Air Reponse, Inc.
    Section of 14 CFR Affected:
    14 CFR 91.313(a)(1), (c), and (d).
    Description of Relief Sought: International Air Reponse, Inc.
requests relief from pertinent sections of Sec.  91.313 to allow
parachuting operations to be conducted for compensation or hire in its
Lockheed C-130A aircraft holding restricted category airworthiness
certificates in support of motion picture production.

[FR Doc. 2011-12431 Filed 5-19-11; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 80, Number 249 (Tuesday, December 29, 2015)]
[Notices]
[Page 81304]
[FR Doc No: 2015-32695]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ID-7551-002]

Zapalac, Will; Notice of Filing

    Take notice that on December 21, 2015, Will Zapalac submitted for
filing, an application for authority to hold interlocking positions,
pursuant to section 305(b) of the Federal Power Act (FPA) \1\ and Part
45 of the Federal Energy Regulatory Commission's (Commission) \2\ Rules
of Practice and Procedure.
---------------------------------------------------------------------------

    \1\ 16 U.S.C. 825d(b) (2012).
    \2\ 18 CFR part 45 (2015).
---------------------------------------------------------------------------

    Any person desiring to intervene or to protest this filing must
file in accordance with Rules 211 and 214 of the Commission's Rules of
Practice and Procedure (18 CFR 385.211, 385.214). Protests will be
considered by the Commission in determining the appropriate action to
be taken, but will not serve to make protestants parties to the
proceeding. Any person wishing to become a party must file a notice of
intervention or motion to intervene, as appropriate. Such notices,
motions, or protests must be filed on or before the comment date. On or
before the comment date, it is not necessary to serve motions to
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper using the ``eFiling'' link at http://www.ferc.gov. Persons unable to file electronically should submit an
original and 5 copies of the protest or intervention to the Federal
Energy Regulatory Commission, 888 First Street NE., Washington, DC
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the
``eLibrary'' link and is available for electronic review in the
Commission's Public Reference Room in Washington, DC. There is an
``eSubscription'' link on the Web site that enables subscribers to
receive email notification when a document is added to a subscribed
docket(s). For assistance with any FERC Online service, please email
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For
TTY, call<PHONE_NUMBER>.
    Comment Date: 5:00 p.m. Eastern Time on January 11, 2016.

    Dated: December 22, 2015.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2015-32695 Filed 12-28-15; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register Volume 79, Number 205 (Thursday, October 23, 2014)]
[Notices]
[Page 63392]
[FR Doc No: 2014-25223]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER15-103-000]

Invenergy Nelson LLC; Supplemental Notice That Initial Market-
Based Rate Filing Includes Request for Blanket Section 204
Authorization

    This is a supplemental notice in the above-referenced proceeding of
Invenergy Nelson LLC's application for market-based rate authority,
with an accompanying rate tariff, noting that such application includes
a request for blanket authorization, under 18 CFR part 34, of future
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE., Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability, is November 5, 2014.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically should submit an original and
5 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First Street NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by clicking on the appropriate link in
the above list. They are also available for electronic review in the
Commission's Public Reference Room in Washington, DC. There is an
eSubscription link on the Web site that enables subscribers to receive
email notification when a document is added to a subscribed docket(s).
For assistance with any FERC Online service, please email
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For
TTY, call<PHONE_NUMBER>.

    Dated: October 16, 2014.
Kimberly D. Bose,
Secretary.
[FR Doc. 2014-25223 Filed 10-22-14; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 76, Number 176 (Monday, September 12, 2011)]
[Notices]
[Pages 56205-56206]
[FR Doc No: 2011-23185]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0002]

Request for Notification From Industry Organizations Interested
in Participating in the Selection Process for Nonvoting Industry
Representatives and Request for Nominations for Nonvoting Industry
Representatives on the Tobacco Products Scientific Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting that
industry organizations interested in participating in the selection of
nonvoting industry representatives to serve on its Tobacco Products
Scientific Advisory Committee, notify FDA in writing. FDA is also
requesting nominations for nonvoting industry representatives to serve
on the Tobacco Products Scientific Advisory Committee. A nominee may
either be self-nominated or nominated by an organization to serve as a
nonvoting industry representative. Nominations will be accepted for
upcoming vacancies effective with this notice.

DATES: Send letters stating interest in participating in the selection
process to FDA by October 12, 2011 (see sections I and II of this
document for details). Concurrently, nomination material for
prospective candidates should be sent to FDA by October 12, 2011.

ADDRESSES: All letters of interest and nominations should be submitted
in writing to<EMAIL_ADDRESS>or by mail to Caryn Cohen, Center for
Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850.

FOR FURTHER INFORMATION CONTACT: Caryn Cohen, Center for Tobacco
Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 1-877-287-1373 (choose Option 4), FAX: 240-276-
3761, e-mail<EMAIL_ADDRESS>

SUPPLEMENTARY INFORMATION: The Agency requests nominations for
nonvoting industry representatives on the Tobacco Products Scientific
Advisory Committee.

I. Tobacco Products Scientific Advisory Committee

    The Tobacco Products Scientific Advisory Committee (the Committee)
advises the Commissioner of Food and Drugs (the Commissioner) or
designee in discharging responsibilities as they relate to the
regulation of tobacco products. The Committee reviews and evaluates
safety, dependence, and health issues relating to tobacco products and
provides appropriate advice, information, and recommendations to the
Commissioner.
    The Committee includes three nonvoting members who represent
industry interests. These members include one representative of the
tobacco manufacturing industry, one representative of the interests of
tobacco growers, and one representative of the interests of the small
business tobacco manufacturing industry. The representative of the
interests of the small business tobacco manufacturing industry may be
filled on a rotating, sequential basis by representatives of different
small business tobacco manufacturers based on areas of expertise
relevant to the topics being considered by the Committee.
    With this notice, nominations are sought for the following
positions: (1) One representative of the interests of tobacco growers,
and an alternate to this representative; (2) a pool of individuals,
with varying areas of expertise, to represent the interests of the
small business tobacco manufacturing industry on a rotating, sequential
basis; and (3) an individual to serve as alternate to the
representative of the tobacco manufacturing industry.

II. Selection Procedure

    Any industry organization interested in participating in the
selection of appropriate nonvoting member(s) to represent industry
interests should send a letter stating that interest to the FDA contact
(see FOR FURTHER INFORMATION CONTACT and DATES). Within the subsequent
30 days, FDA will send a letter to each organization that has expressed
an interest, attaching a complete list of all such organizations, and a
list of all nominees along with their current resumes. The letter will
also state that it is the responsibility of the interested
organizations to confer with one another and to select a candidate,
within 60 days after the receipt of the letter, to serve as the
nonvoting member to represent industry interests on the Committee. The
interested organizations are not bound by the list of nominees in
selecting a candidate. However, if no individual is selected within 60
days, the Commissioner will select the nonvoting member to represent
the industry interests.

III. Application Procedure

    Individuals may self-nominate and/or organizations may nominate one
or more individuals to serve as a nonvoting industry representative
(for the roles specified in this document). Nominations must include a
current resume or curriculum vitae of the nominee including current
business address and/or home address, telephone number, e-mail address
if available, and the role for which the individual is being nominated.
Nominations must also acknowledge that the nominee is aware of the
nomination unless self-nominated. FDA will forward all nominations to
the organizations expressing interest in participating in the selection
process for the committee. (Persons who nominate themselves as
nonvoting industry representatives will not participate in the
selection process.)
    FDA has a special interest in ensuring that women, minority groups,
and individuals with physical disabilities are adequately represented
on its advisory committees and, therefore, encourages nominations for
appropriately qualified candidates from these groups.
    This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: September 7, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-23185 Filed 9-9-11; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register: January 22, 2009 (Volume 74, Number 13)]
[Notices]
[Page 4032]
[DOCID:fr22ja09-41]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER09-498-000]

Vickers Power, LLC; Supplemental Notice That Initial Market-Based
Rate Filing Includes Request for Blanket Section 204 Authorization

January 13, 2009.
    This is a supplemental notice in the above-referenced proceeding of
Vickers Power, LLC's application for market-based rate authority, with
an accompanying rate tariff, noting that such application includes a
request for blanket authorization, under 18 CFR Part 34, of future
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street, NE.,
Washington, DC 20426, in accordance with Rules 211 and 214 of the
Commission's Rules of Practice and Procedure (18 CFR 385.211 and
385.214). Anyone filing a motion to intervene or protest must serve a
copy of that document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability, is February 2, 2009.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://
www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically should submit an original and
14 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First St., NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by clicking on the appropriate link in
the above list. They are also available for review in the Commission's
Public Reference Room in Washington, DC. There is an eSubscription link
on the Web site that enables subscribers to receive e-mail notification
when a document is added to a subscribed dockets(s). For assistance
with any FERC Online service, please e-mail<EMAIL_ADDRESS>
or call<PHONE_NUMBER> (toll free). For TTY, call<PHONE_NUMBER>.

Kimberly D. Bose,
Secretary.
[FR Doc. E9-1134 Filed 1-21-09; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register Volume 78, Number 102 (Tuesday, May 28, 2013)]
[Rules and Regulations]
[Page 31840]
[FR Doc No: 2013-12542]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 117

[Docket No. USCG-2013-0370]

Drawbridge Operation Regulation; Cumberland River, Nashville, TN

AGENCY: Coast Guard, DHS.

ACTION: Notice of deviation from drawbridge regulation.

-----------------------------------------------------------------------

SUMMARY: The Coast Guard has issued a temporary deviation from the
operating schedule that governs the Louisville and Nashville Railroad
Drawbridge across the Cumberland River, mile 190.4, at Nashville,
Tennessee. The deviation is necessary to allow the bridge owner time to
perform preventive maintenance that is essential to the continued safe
operation of the drawbridge. This deviation allows the bridge to remain
in the closed-to-navigation position while a worn gear and shaft
assembly are replaced.

DATES: This deviation is effective from 8 a.m., May 28, 2013 to 6 p.m.,
May 29, 2013.

ADDRESSES: The docket for this deviation, [USCG-2013-0370] is available
at http://www.regulations.gov. Type the docket number in the ``SEARCH''
box and click ``SEARCH.'' Click on Open Docket Folder on the line
associated with this deviation. You may also visit the Docket
Management Facility in Room W12-140 on the ground floor of the
Department of Transportation West Building, 1200 New Jersey Avenue SE.,
Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays.

FOR FURTHER INFORMATION CONTACT: If you have questions on this
temporary deviation, call or email Eric A. Washburn, Bridge
Administrator, Western Rivers, Coast Guard; telephone<PHONE_NUMBER>,
email<EMAIL_ADDRESS>If you have questions on viewing the
docket, call Barbara Hairston, Program Manager, Docket Operations,
telephone<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: The CSX Transportation, Inc. requested a
temporary deviation for the Louisville and Nashville Railroad
Drawbridge, across the Cumberland River, mile 190.4, at Nashville,
Tennessee to remain in the closed-to-navigation position while a worn
gear and shaft assembly are replaced. The closure period will start at
8 a.m., May 28, 2013 to 6 p.m., May 29, 2013.
    Once the worn gear and shaft assembly are removed, the swing span
will not be able to open, even for emergencies, until the replacement
of the gear and shaft assembly is installed.
    The Louisville and Nashville Railroad Drawbridge currently operates
in accordance with 33 CFR 117.5, which states the general requirement
that drawbridges shall open promptly and fully for the passage of
vessels when a request to open is given in accordance with the subpart.
In order to facilitate the needed bridge work, the drawbridge must be
kept in the closed-to-navigation position.
    There are no alternate routes for vessels transiting this section
of the Cumberland River.
    The Louisville and Nashville Railroad Drawbridge, in the closed-to-
navigation position, provides a vertical clearance of 47 feet above
normal pool. Navigation on the waterway consists primarily of
commercial tows and recreational watercraft. This temporary deviation
has been coordinated with the waterway users. No objections were
received.
    In accordance with 33 CFR 117.35(e), the drawbridge must return to
its regular operating schedule immediately at the end of the designated
period of this temporary deviation. This deviation from the operating
regulations is authorized under 33 CFR 117.35.

    Dated: May 8, 2013.
Eric A. Washburn,
Bridge Administrator, Western Rivers.
[FR Doc. 2013-12542 Filed 5-24-13; 8:45 am]
BILLING CODE 9110-04-P


			  UNITED STATES OF AMERICA

		        DEPARTMENT OF TRANSPORTATION

			  OFFICE OF THE SECRETARY

			          WASHINGTON, D.C.

Issued by the Department of Transportation on November 25, 2003

NOTICE OF ACTION TAKEN -- DOCKET OST-2003-16316

________________________________________________________________________
__________________________________________

This serves as notice to the public of the action described below, taken
by the Department official indicated (no additional confirming order
will be issued in this matter).

Applicant:  Hapag-Lloyd Express GmbH.				Date Filed:  October 10, 2003

Relief requested: Exemption from 49 U.S.C. § 41301 to engage in charter
foreign air transportation of persons, property and mail (1) between any
point or points in Germany and any point or points in the United States;

(2) between any point or points in the United States and any point or
points in a third country or countries, provided that, except with
respect to cargo charters, such service constitutes part of a continuous
operation, with or without a change of aircraft, that includes service
to Germany for the purpose of carrying local traffic between Germany and
the United States; and (3) other charters in accordance with Part 212 of
the Department’s rules.  Hapag-Lloyd states that its services will be
provided with small aircraft.

If renewal, date and citation of last action:  New authority

Applicant representative:  Gary B. Garofalo<PHONE_NUMBER>

DOT Analyst:  Gordon H. Bingham<PHONE_NUMBER>

Responsive pleadings:  None filed

	DISPOSITION

Action:  Approved							Action date:  November 25, 2003

Effective dates of authority granted:  November 25, 2003-November 25,
2005.

Basis for approval (bilateral agreement/reciprocity):  Air Transport
Agreement between the United States and Germany

Except to the extent exempted/waived, this authority is subject to the
terms, conditions, and limitations indicated:  X  Standard exemption
conditions (Attached)

Special conditions/Partial grant/Denial basis/Remarks:  Based on the
record in this case, we found that Hapag-Lloyd is operationally
qualified to perform the services authorized above.  As to its financial
qualifications, Hapag-Lloyd has provided financial information which
indicates that it can conduct the proposed services without jeopardizing
passenger or shipper funds.  We also found that Hapag-Lloyd is
substantially owned and effectively controlled by citizens of Germany.
In addition, all of Hapag-Lloyd’s officers and key management
personnel are citizens of Germany.  By memorandum dated November 24,
2003, the FAA advised us that it knows of no reason why we should act
unfavorably on Hapag-Lloyd’s application.

In the conduct of the service authorized above, Hapag-Lloyd Express
shall use only small aircraft (i.e., aircraft designed to have a maximum
passenger capacity of not more than 60 seats or a maximum payload
capacity of not more than 18,000 pounds).

2

Action taken by:  Paul L. Gretch, Director

		     Office of International Aviation

________________________________________________________________________
__________________________________________

Under authority assigned by the Department in its regulations, 14 CFR
Part 385, we found that (1) the applicant was qualified to perform the
proposed operations; (2) our action was consistent with Department
policy; (3) grant of the authority was consistent with the public
interest; and (4) grant of the authority would not constitute a major
regulatory action under the Energy Policy and Conservation Act of 1975.
To the extent not granted/deferred/dismissed, we denied all requests in
the referenced Docket.  We may amend, modify, or revoke the authority
granted in this Notice at any time without hearing at our discretion.

Persons entitled to petition the Department for review of the action set
forth in this Notice under the Department’s regulations, 14 CFR §
385.30, may file their petitions within seven (7) days after the date of
issuance of this Notice.  This action was effective when taken, and the
filing of a petition for review will not alter such effectiveness.

An electronic version of this document is available on the World Wide
Web at:

  HYPERLINK "http://dms.dot.gov//reports/reports_aviation.asp"
http://dms.dot.gov//reports/reports_aviation.asp

			Attachment

Foreign Carrier Conditions

In the conduct of the operations authorized, the foreign carrier
applicant(s) shall:

(1)  Not conduct any operations unless it holds a currently effective
authorization from its homeland for such operations, and it has filed a
copy of such authorization with the Department;

(2)  Comply with all applicable requirements of the Federal Aviation
Administration, including, but not limited to, 14 CFR Parts 129, 91, and
36, and with all applicable U.S. Government requirements concerning
security.  To assure compliance with all applicable U.S. Government
requirements concerning security, the holder shall, before commencing
any new service (including charter flights) from a foreign airport that
would be the holder’s last point of departure for the United States,
contact its Principal Security Inspector (PSI) to advise the PSI of its
plans and to find out whether the Transportation Security Administration
has determined that security is adequate to allow such airport(s) to be
served;

(3)  Comply with the requirements for minimum insurance coverage
contained in 14 CFR Part 205, and, prior to the commencement of any
operations under this authority, file evidence of such coverage, in the
form of a completed OST Form 6411, with the Federal Aviation
Administration’s Program Management Branch (AFS-260), Flight Standards
Service (any changes to, or termination of, insurance also shall be
filed with that office);

(4)  Not operate aircraft under this authority unless it complies with
operational safety requirements at least equivalent to Annex 6 of the
Chicago Convention;

(5)  Conform to the airworthiness and airman competency requirements of
its Government for international air services;

(6)  Except as specifically exempted or otherwise provided for in a
Department Order, comply with the requirements of 14 CFR Part 203,
concerning waiver of Warsaw Convention liability limits and defenses;

(7)  Agree that operations under this authority constitute a waiver of
sovereign immunity, for the purposes of 28 U.S.C. 1605(a), but only with
respect to those actions or proceedings instituted against it in any
court or other tribunal in the United States that are: (a)  based on its
operations in international air transportation that, according to the
contract of carriage, include a point in the United States as a point of
origin, point of destination, or agreed stopping place, or for which the
contract of carriage was purchased in the United States; or (b)  based
on a claim under any international agreement or treaty cognizable in any
court or other tribunal of the United States.  In this condition, the
term "international air transportation" means "international
transportation" as defined by the Warsaw Convention, except that all
States shall be considered to be High Contracting Parties for the
purpose of this definition;

(8)  Except as specifically authorized by the Department, originate or
terminate all flights to/from the United States in its homeland;

(9)  Comply with the requirements of 14 CFR Part 217, concerning the
reporting of scheduled, nonscheduled, and charter data;

(10) If charter operations are authorized, except as otherwise provided
in the applicable aviation agreement, comply with the Department's rules
governing charters (including 14 CFR Parts 212 and 380); and

(11) Comply with such other reasonable terms, conditions, and
limitations required by the public interest as may be prescribed by the
Department, with all applicable orders or regulations of other U.S.
agencies and courts, and with all applicable laws of the United States.

This authority shall not be effective during any period when the holder
is not in compliance with the conditions imposed above.  Moreover, this
authority cannot be sold or otherwise transferred without explicit
Department approval under Title 49 of the U.S. Code.

  Hapag-Lloyd’s application was accompanied by a motion under Rule 12
(14 CFR § 302.12) to withhold certain financial information from public
disclosure.  Hapag-Lloyd states that it is a privately held German
company, and as such, is not required by its government to disclose such
information.  Hapag-Lloyd states that disclosure of such information
would adversely affect Hapag-Lloyd’s competitive interest vis a vis
its commercial competitors and is not required by the public interest.
We have reviewed the documents under the disclosure guidelines of Rule
12 and have determined that they warrant confidential treatment.
Because of the commercially sensitive nature of the information, we have
determined that the documents fall within the Freedom of Information Act
exemption for proprietary information and would adversely affect the
competitive position of Hapag-Lloyd under 49 U.S.C. § 40115.

  Hapag-Lloyd is a wholly owned subsidiary of TUI AG, a German
corporation.


[Federal Register Volume 85, Number 15 (Thursday, January 23, 2020)]
[Notices]
[Pages 3925-3929]
[FR Doc No: 2020-01073]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0618]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Electronic Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the

Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on requirements for reporting and
recordkeeping, general and specific requirements, and the availability
of sample electronic products for manufacturers and distributors of
electronic products.

DATES: Submit either electronic or written comments on the collection
of information by March 23, 2020.

ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before March 23, 2020. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of March 23, 2020. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2013-N-0618 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Electronic Products.'' Received
comments, those filed in a timely manner (see ADDRESSES), will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852,<PHONE_NUMBER>,
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3521), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
    With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Electronic Products--21 CFR Parts 1000 Through 1050

OMB Control Number 0910-0025--Extension

    Under sections 532 through 542 of the Federal Food, Drug, and
Cosmetic Act (FD&C Act) (21 U.S.C. 360ii through 360ss), FDA has the
responsibility to protect the public from unnecessary exposure of
radiation from electronic products. The regulations issued under these
authorities are listed in Title 21 of the Code of Federal Regulations,
chapter

I, subchapter J, parts 1000 through 1050 (21 CFR parts 1000 through
1050).
    Section 532 of the FD&C Act directs the Secretary of Health and
Human Services (the Secretary), to establish and carry out an
electronic product radiation control program, including the
development, issuance, and administration of performance standards to
control the emission of electronic product radiation from electronic
products. The program is designed to protect the public health and
safety from electronic radiation, and the FD&C Act authorizes the
Secretary to procure (by negotiation or otherwise) electronic products
for research and testing purposes and to sell or otherwise dispose of
such products. Section 534(g) of the FD&C Act directs the Secretary to
review and evaluate industry testing programs on a continuing basis;
and section 535(e) and (f) of the FD&C Act directs the Secretary to
immediately notify manufacturers of, and ensure correction of,
radiation defects or noncompliance with performance standards. Section
537(b) of the FD&C Act contains the authority to require manufacturers
of electronic products to establish and maintain records (including
testing records), make reports, and provide information to determine
whether the manufacturer has acted in compliance.
    The regulations under parts 1002 through 1010 specify reports to be
provided by manufacturers and distributors to FDA and records to be
maintained in the event of an investigation of a safety concern or a
product recall. FDA conducts laboratory compliance testing of products
covered by regulations for product standards in parts 1020, 1030, 1040,
and 1050.
    FDA details product-specific performance standards that specify
information to be supplied with the product or require specific
reports. The information collections are either specifically called for
in the FD&C Act or were developed to aid the Agency in performing its
obligations under the FD&C Act. The data reported to FDA and the
records maintained are used by FDA and the industry to make decisions
and take actions that protect the public from radiation hazards
presented by electronic products. This information refers to the
identification of, location of, operational characteristics of, quality
assurance programs for, and problem identification and correction of
electronic products. The data provided to users and others are intended
to encourage actions to reduce or eliminate radiation exposures.
    FDA uses the following forms to aid respondents in the submission
of information for this information collection:

 Form FDA 2579 ``Report of Assembly of a Diagnostic X-Ray
System''
 Form FDA 2767 ``Notice of Availability of Sample Electronic
Product''
 Form FDA 2877 ``Declaration for Imported Electronic Products
Subject to Radiation Control Standards''
 Form FDA 3649 ``Accidental Radiation Occurrence (ARO)''
 Form FDA 3626 ``A Guide for the Submission of Initial Reports
on Diagnostic X-Ray Systems and Their Major Components''
 Form FDA 3627 ``Diagnostic X-Ray CT Products Radiation Safety
Report''
 Form FDA 3628 ``General Annual Report (Includes Medical,
Analytical, and Industrial X-Ray Products Annual Report)''
 Form FDA 3629 ``Abbreviated Report''
 Form FDA 3630 ``Guide for Preparing Product Reports on
Sunlamps and Sunlamp Products''
 Form FDA 3631 ``Guide for Preparing Annual Reports on
Radiation Safety Testing of Sunlamp Products''
 Form FDA 3632 ``Guide for Preparing Product Reports on Lasers
and Products Containing Lasers''
 Form FDA 3633 ``General Variance Request''
 Form FDA 3634 ``Television Products Annual Report''
 Form FDA 3635 ``Laser Light Show Notification''
 Form FDA 3636 ``Guide for Preparing Annual Reports on
Radiation Safety Testing of Laser and Laser Light Show Products''
 Form FDA 3637 ``Laser Original Equipment Manufacturer (OEM)
Report''
 Form FDA 3638 ``Guide for Filing Annual Reports for X-Ray
Components and Systems''
 Form FDA 3639 ``Guidance for the Submission of Cabinet X-Ray
System Reports Pursuant to 21 CFR 1020.40''
 Form FDA 3640 ``Reporting Guide for Laser Light Shows and
Displays''
 Form FDA 3147 ``Application for a Variance From 21 CFR
1040.11(c) for a Laser Light Show, Display, or Device''
 Form FDA 3641 ``Cabinet X-Ray Annual Report''
 Form FDA 3642 ``General Correspondence''
 Form FDA 3643 ``Microwave Oven Products Annual Report''
 Form FDA 3644 ``Guide for Preparing Product Reports for
Ultrasonic Therapy Products''
 Form FDA 3645 ``Guide for Preparing Annual Reports for
Ultrasonic Therapy Products''
 Form FDA 3646 ``Mercury Vapor Lamp Products Radiation Safety
Report''
 Form FDA 3647 ``Guide for Preparing Annual Reports on
Radiation Safety Testing of Mercury Vapor Lamps''
 Form FDA 3659 ``Reporting and Compliance Guide for Television
Products''
 Form FDA 3660 ``Guidance for Preparing Reports on Radiation
Safety of Microwave Ovens''
 Form FDA 3661 ``A Guide for the Submission of an Abbreviated
Report on X-Ray Tables, Cradles, Film Changers, or Cassette Holders
Intended for Diagnostic Use''
 Form FDA 3662 ``A Guide for the Submission of an Abbreviated
Radiation Safety Report on Cephalometric Devices Intended for
Diagnostic Use''
 Form FDA 3663 ``Abbreviated Reports on Radiation Safety for
Microwave Products (Other than Microwave Ovens)''
 Form FDA 3801 ``Guide for Preparing Initial Reports and Model
Change Reports on Medical Ultraviolet Lamps and Products Containing
Such Lamps''

    The respondents to this information collection are electronic
product and x-ray manufacturers, importers, and assemblers. The burden
estimates were derived by consultation with FDA and industry personnel,
and are based on data collected from industry, including product report
submissions. An evaluation of the type and scope of information
requested was also used to derive some time estimates.
    FDA estimates the burden of this collection of information as
follows:

                                                      Table 1--Estimated Annual Reporting Burden 1
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                Number of                        Average
          Activity/21 CFR section                     FDA form               Number of     responses per   Total annual     burden per     Total hours 2
                                                                            respondents     respondent       responses       response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Product reports--1002.10(a) through (k)...  3626--Diagnostic x-ray,                1,400             2.2           3,080              24          73,920
                                             3627--CT x-ray, 3639--
                                             Cabinet x-ray, 3632--Laser,
                                             3640--Laser light show,
                                             3630--Sunlamp, 3646--
                                             Mercury vapor lamp, 3644--
                                             Ultrasonic therapy, 3659--
                                             TV, 3660--Microwave oven,
                                             3801--UV lamps.
Product safety or testing changes--         ............................             480             2.5           1,200             0.5             600
 1002.11(a) and (b).
Abbreviated reports--1002.12..............  3629--General abbreviated                 60             1.8             108               5             540
                                             report, 3661--X-ray tables,
                                             etc., 3662--Cephalometric
                                             device, 3663--Microwave
                                             products (non-oven).
Annual reports--1002.13(a) and (b)........  3628--General, 3634--TV,               1,660             1.3           2,158              18          38,844
                                             3638--Diagnostic x-ray,
                                             3641--Cabinet x-ray, 3643--
                                             Microwave oven, 3636--
                                             Laser, 3631--Sunlamp, 3647--
                                             Mercury vapor lamp, 3645--
                                             Ultrasonic therapy.
Quarterly updates for new models--          ............................             120             1.4             168             0.5              84
 1002.13(c).
Accidental radiation occurrence reports--   3649--ARO...................              30             6.7             201               2             402
 1002.20.
Exemption requests--1002.50(a) and 1002.51  3642--General correspondence               4             1.3               5               1               5
Product and sample information--1005.10...  2767--Sample product........               5               1               5             0.1               1
Identification information and compliance   2877--Imports declaration...          12,620             2.5          31,550             0.2           6,310
 status--1005.25.
Alternate means of certification--          ............................               1               2               2               5              10
 1010.2(d).
Variance--1010.4(b).......................  3633--General variance                   350             1.1             385             1.2             462
                                             request, 3147--Laser show
                                             variance request, 3635--
                                             Laser show notification.
Exemption from performance standards--      ............................               1               1               1              22              22
 1010.5(c) and (d).
Alternate test procedures--1010.13........  ............................               1               1               1              10              10
Report of assembly of diagnostic x-ray      2579--Assembler report......           1,230              34          41,820            0.30          12,546
 components--1020.30(d), and (d)(1) and
 (2).
Microwave oven exemption from warning       ............................               1               1               1               1               1
 labels--1030.10(c)(6)(iv).
Laser products registration--               3637--Original equipment                  70             2.9             203               3             609
 1040.10(a)(3)(i).                           manufacturer (OEM) report.
                                                                         -------------------------------------------------------------------------------
    Total.................................  ............................  ..............  ..............  ..............  ..............         134,366
--------------------------------------------------------------------------------------------------------------------------------------------------------
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
2 Total hours have been rounded.

                                Table 2--Estimated Annual Recordkeeping Burden 1
----------------------------------------------------------------------------------------------------------------
                                                     Number of                        Average
     Activity/21 CFR section         Number of      records per    Total annual     burden per     Total hours 2
                                   recordkeepers   recordkeeper       records      recordkeeping
----------------------------------------------------------------------------------------------------------------
Manufacturers records--1002.30             1,650           1,650       2,722,500            0.12         326,700
 and 1002.31(a).................
Dealer/distributor records--               3,110              50         155,500            0.05           7,775
 1002.40 and 1002.41............
Information on diagnostic x-ray               50               1              50             0.5              25
 systems--1020.30(g)............
Laser products distribution                   70               1              70               1              70
 records--1040.10(a)(3)(ii).....
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............         334,570
----------------------------------------------------------------------------------------------------------------
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
2 Total hours have been rounded.

                            Table 3--Estimated Annual Third-Party Disclosure Burden 1
----------------------------------------------------------------------------------------------------------------
                                                     Number of                        Average
     Activity/21 CFR section         Number of      disclosures    Total annual     burden per     Total hours 2
                                    respondents   per respondent    disclosures     disclosure
----------------------------------------------------------------------------------------------------------------
Technical and safety information               1               1               1              12              12
 for users--1002.3..............
Dealer/distributor records--                  30               3              90               1              90
 1002.40 and 1002.41............

Television receiver critical                   1               1               1               1               1
 component warning--
 1020.10(c)(4)..................
Cold cathode tubes--                           1               1               1               1               1
 1020.20(c)(4)..................
Information on diagnostic x-ray                6               1               6              55             330
 systems--1020.30(g)............
Statement of maximum line                      6               1               6              10              60
 current of x-ray systems--
 1020.30(g)(2)..................
Diagnostic x-ray system safety                 6               1               6             200           1,200
 and technical information--
 1020.30(h)(1) through (4)......
Fluoroscopic x-ray system safety               5               1               5              25             125
 and technical information--
 1020.30(h)(5) and (6) and
 1020.32(a)(1), (g), and (j)(4).
CT equipment--1020.33(c), (d),                 5               1               5             150             750
 (g)(4), and (j)................
Cabinet x-ray systems                          6               1               6              40             240
 information--1020.40(c)(9)(i)
 and (ii).......................
Microwave oven radiation safety                1               1               1              20              20
 instructions--1030.10(c)(4)....
Microwave oven safety                          1               1               1              20              20
 information and instructions--
 1030.10(c)(5)(i) through (iv)..
Microwave oven warning labels--                1               1               1               1               1
 1030.10(c)(6)(iii).............
Laser products information--                   3               1               3              20              60
 1040.10(h)(1)(i) through (vi)..
Laser product service                          3               1               3              20              60
 information--1040.10(h)(2)(i)
 and (ii).......................
Medical laser product                          2               1               2              10              20
 instructions--1040.11(a)(2)....
Sunlamp products instructions--                1               1               1              10              10
 1040.20........................
Mercury vapor lamp labeling--                  1               1               1               1               1
 1040.30(c)(1)(ii)..............
Mercury vapor lamp permanently                 1               1               1               1               1
 affixed labels--1040.30(c)(2)..
Ultrasonic therapy products--                  1               1               1              56              56
 1050.10(d)(1) through (d),
 (f)(1), and (f)(2)(iii)........
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............           3,058
----------------------------------------------------------------------------------------------------------------
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
2 Total hours have been rounded.

    Based on a review of the information collection, we have made no
adjustments to our burden estimate.

    Dated: January 14, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-01073 Filed 1-22-20; 8:45 am]
 BILLING CODE 4164-01-P


     UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

                             OFFICE OF CHEMICAL SAFETY
AND POLLUTION PREVENTION
MEMORANDUM FOR THE RECORD

RE:  	Meeting with Eastman on the Regulation of Persistent, Bioaccumulative, and Toxic Chemicals Under TSCA Section 6(h)
List of Contents
 Meeting Summary
 Attendees
Meeting Summary

On July 13, 2022, representatives from EPA met with Eastman to discuss comments submitted in docket EPA-HQ-OPPT-2021-0598 on the Regulation of Persistent, Bioaccumulative, and Toxic Chemicals Under TSCA Section 6(h); Phenol, Isopropylated Phosphate (3:1); Compliance Date Extension, published March 8, 2022. During the meeting, Eastman presented an overview of their use of PIP (3:1) in aviation and hydraulic fluids, and in lubricants and greases, including current worker protection measures and estimated timelines for finding alternative chemistries. EPA gave an overview of the TSCA section 6(h) rulemaking activities to date. Eastman indicated they would continue engaging with the EPA rulemaking process, in particular with respect to lubricants and greases.

Attendees
EPA:
Niva Kramek
Cindy Wheeler
Gabriela Rossner

Eastman:
Emily Clark
Hannah Hill
Sarah Cieluskowsky
John Hott


[Federal Register Volume 82, Number 198 (Monday, October 16, 2017)]
[Rules and Regulations]
[Pages 48000-48005]
[FR Doc No: 2017-22356]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA-HQ-OPP-2016-0142; FRL-9966-13]

Triflumezopyrim; Pesticide Tolerances

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This regulation establishes tolerances for residues of
triflumezopyrim in or on rice, grain and rice, hulls. E.I. Dupont de
Nemours and Company requested these tolerances under the Federal Food,
Drug, and Cosmetic Act (FFDCA).

DATES: This regulation is effective October 16, 2017. Objections and
requests for hearings must be received on or before December 15, 2017,
and must be filed in accordance with the instructions provided in 40
CFR part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).

ADDRESSES: The docket for this action, identified by docket
identification (ID) number EPA-HQ-OPP-2016-0142, is available at http://www.regulations.gov or at the Office of Pesticide Programs Regulatory
Public Docket (OPP Docket) in the Environmental Protection Agency
Docket Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334,
1301 Constitution Ave. NW., Washington, DC 20460-0001. The Public
Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through
Friday, excluding legal holidays. The telephone number for the Public
Reading Room is<PHONE_NUMBER>, and the telephone number for the OPP
Docket is<PHONE_NUMBER>. Please review the visitor instructions and
additional information about the docket available at http://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Michael L. Goodis, Registration
Division (7505P), Office of Pesticide Programs, Environmental
Protection Agency, 1200 Pennsylvania Ave. NW., Washington, DC 20460-
0001; main telephone number:<PHONE_NUMBER>; email address:
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
The following list of North American Industrial Classification System
(NAICS) codes is not intended to be exhaustive, but rather provides a
guide to help readers determine whether this document applies to them.
Potentially affected entities may include:
     Crop production (NAICS code 111).
     Animal production (NAICS code 112).
     Food manufacturing (NAICS code 311).
     Pesticide manufacturing (NAICS code 32532).

B. How can I get electronic access to other related information?

    You may access a frequently updated electronic version of EPA's
tolerance regulations at 40 CFR part 180 through the Government
Printing Office's e-CFR site at http://www.ecfr.gov/cgi-bin/text-idx?&c=ecfr&tpl=/ecfrbrowse/Title40/40tab_02.tpl. To access the OCSPP
test

guidelines referenced in this document electronically, please go to
http://www.epa.gov/ocspp and select ``Test Methods and Guidelines.''

C. How can I file an objection or hearing request?

    Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an
objection to any aspect of this regulation and may also request a
hearing on those objections. You must file your objection or request a
hearing on this regulation in accordance with the instructions provided
in 40 CFR part 178. To ensure proper receipt by EPA, you must identify
docket ID number EPA-HQ-OPP-2016-0142 in the subject line on the first
page of your submission. All objections and requests for a hearing must
be in writing, and must be received by the Hearing Clerk on or before
December 15, 2017. Addresses for mail and hand delivery of objections
and hearing requests are provided in 40 CFR 178.25(b).
    In addition to filing an objection or hearing request with the
Hearing Clerk as described in 40 CFR part 178, please submit a copy of
the filing (excluding any Confidential Business Information (CBI)) for
inclusion in the public docket. Information not marked confidential
pursuant to 40 CFR part 2 may be disclosed publicly by EPA without
prior notice. Submit the non-CBI copy of your objection or hearing
request, identified by docket ID number EPA-HQ-OPP-2016-0142, by one of
the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be CBI or other
information whose disclosure is restricted by statute.
     Mail: OPP Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave., NW., Washington, DC
20460-0001.
     Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at http://www.epa.gov/dockets/contacts.html.
    Additional instructions on commenting or visiting the docket, along
with more information about dockets generally, is available at http://www.epa.gov/dockets.

II. Summary of Petitioned-For Tolerance

    In the Federal Register of April 25, 2016 (81 FR 24044) (FRL-9944-
86), EPA issued a document pursuant to FFDCA section 408(d)(3), 21
U.S.C. 346a(d)(3), announcing the filing of a pesticide petition (PP
6E8448) by E.I. Dupont de Nemours and Company, 974 Centre Road,
Wilmington, DE 19805. The petition requested that 40 CFR part 180 be
amended by establishing tolerances for residues of the insecticide
triflumezopyrim (2,4-dioxo-1-(5-pyrimidinylmethyl)-3-[3-
(trifluoromethyl)phenyl]-2H-pyrido[1,2-a]pyrimidinium inner salt), in
or on rice, grain at 0.20 parts per million (ppm). That document
referenced a summary of the petition prepared by E.I. Dupont de Nemours
and Company, the registrant, which is available in the docket, http://www.regulations.gov. There were no comments received in response to the
notice of filing.
    Based upon review of the data supporting the petition, EPA has
revised the tolerance for rice, grain to 0.40 ppm based on the OECD
tolerance calculation procedure. Additionally, EPA is requiring a
tolerance for rice, hull at 1.0 ppm. The reason for these changes are
explained in Unit IV.D.

III. Aggregate Risk Assessment and Determination of Safety

    Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a
tolerance (the legal limit for a pesticide chemical residue in or on a
food) only if EPA determines that the tolerance is ``safe.'' Section
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a
reasonable certainty that no harm will result from aggregate exposure
to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable
information.'' This includes exposure through drinking water and in
residential settings, but does not include occupational exposure.
Section 408(b)(2)(C) of FFDCA requires EPA to give special
consideration to exposure of infants and children to the pesticide
chemical residue in establishing a tolerance and to ``ensure that there
is a reasonable certainty that no harm will result to infants and
children from aggregate exposure to the pesticide chemical residue . .
. .''
    Consistent with FFDCA section 408(b)(2)(D), and the factors
specified in FFDCA section 408(b)(2)(D), EPA has reviewed the available
scientific data and other relevant information in support of this
action. EPA has sufficient data to assess the hazards of and to make a
determination on aggregate exposure for triflumezopyrim including
exposure resulting from the tolerances established by this action.
EPA's assessment of exposures and risks associated with triflumezopyrim
follows.

A. Toxicological Profile

    EPA has evaluated the available toxicity data and considered its
validity, completeness, and reliability as well as the relationship of
the results of the studies to human risk. EPA has also considered
available information concerning the variability of the sensitivities
of major identifiable subgroups of consumers, including infants and
children. The most common adverse effect observed across the
triflumezopyrim toxicological database was a decrease in absolute
bodyweight in dogs and rats in both sexes following subchronic and
chronic exposures. No additional non-cancer effects relevant for human
health risk assessment were noted in the subchronic rat and dog oral
toxicity studies. No effects were seen in the mice and rabbit studies,
including the dermal toxicity study.
    Chronic exposures in rats resulted in an increased incidence of
bile duct hyperplasia in the presence of decreases in absolute
bodyweight (~70 milligrams/kilogram/day (mg/kg/day)). Additional
lesions were seen in the liver, testes, and uterus at a higher dose
(~400 mg/kg/day). The rat combined chronic/carcinogenicity study showed
an increase in uterine and liver tumors at a dose of ~400 mg/kg/day,
which is considered excessive for evaluating carcinogenic potential.
The remaining doses were not considered excessive and did not show
treatment-related tumors in either sex. Liver tumors in male mice
during the mouse carcinogenicity study were considered treatment-
related. The proposed mode of action (constitutive androstane receptor
(CAR)-mediated proliferation) for the liver tumors in male mice was
adequately supported by mechanistic data that clearly identified the
sequence of events, dose-response concordance and temporal relationship
for this tumor type. Triflumezopyrim is classified as ``not likely to
be carcinogenic to humans at dose levels that do not cause a
significant induction in CYP2B activity.'' Based on the mechanistic
studies provided, significant induction in CYP2B only occurred at 7,000
ppm (727 mg/kg/day in male mice); the chronic reference dose used for
the Agency's safety assessment is based on a no observed adverse effect
level of 17 mg/kg/day. As a result, the Agency concludes that the
chronic reference dose will be protective of potential carcinogenicity,
which can be assessed through a non-linear approach. There is no
mutagenicity concern based on the results from the in vitro and in vivo
genetic toxicity studies.

    Evidence of increased quantitative susceptibility in the rat
developmental toxicity study was observed in the form of incomplete
ossification of the parietal skull in the fetuses of dams treated with
a relatively high dose (200 mg/kg/day) in the absence of any maternal
toxicity. There was no evidence of susceptibility in the rat
reproduction toxicity or rabbit developmental toxicity study.
    Possible signs of neurotoxicity were observed in the acute
neurotoxicity (ACN) in rats as well as in the 28-day subchronic oral
toxicity study in dogs. An overall decrease in motor activity was
observed in the ACN study on the day of dosing. Animals also showed
slight decreases in body temperature and number of rearing movements,
as well as increases in the incidence of high posture, at a dose 4x
higher than what elicited the decrease in motor activity. The 28-day
subchronic oral toxicity study in dogs showed neurobehavioral signs
such as slight impairment of forelimb and/or hindlimb strength and
effects on pupil constriction. However, the neurobehavioral signs were
not seen in studies of longer duration in dogs.
    Although evidence of neurotoxicity was seen in the ACN study in
rats and 28-day oral toxicity study in dogs, concern is low since: (1)
Effects are well-characterized with clearly established NOAEL/LOAEL
values; (2) no additional neurotoxic effects were seen in the
toxicological database including the subchronic neurotoxicity study
(SCN); (3) there were no corroborating neuropathological findings; (4)
the neurobehavioral signs in the dog were not observed in studies of
longer durations in dogs; and (5) the selected endpoints for risk
assessment are protective of these effects.
    Specific information on the studies received and the nature of the
adverse effects caused by Triflumezopyrim as well as the no-observed-
adverse-effect-level (NOAEL) and the lowest-observed-adverse-effect-
level (LOAEL) from the toxicity studies can be found at http://www.regulations.gov in document Triflumezopyrim: Human Health Risk
Assessment to Establish Tolerances for Rice Without U.S. Registration
at page 21 in docket ID number EPA-HQ-OPP-2016-0142.

B. Toxicological Points of Departure/Levels of Concern

    Once a pesticide's toxicological profile is determined, EPA
identifies toxicological points of departure (POD) and levels of
concern to use in evaluating the risk posed by human exposure to the
pesticide. For hazards that have a threshold below which there is no
appreciable risk, the toxicological POD is used as the basis for
derivation of reference values for risk assessment. PODs are developed
based on a careful analysis of the doses in each toxicological study to
determine the dose at which no adverse effects are observed (the NOAEL)
and the lowest dose at which adverse effects of concern are identified
(the LOAEL). Uncertainty/safety factors are used in conjunction with
the POD to calculate a safe exposure level--generally referred to as a
population-adjusted dose (PAD) or a reference dose (RfD)--and a safe
margin of exposure (MOE). For non-threshold risks, the Agency assumes
that any amount of exposure will lead to some degree of risk. Thus, the
Agency estimates risk in terms of the probability of an occurrence of
the adverse effect expected in a lifetime. For more information on the
general principles EPA uses in risk characterization and a complete
description of the risk assessment process, see https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/guidance-human-health-risk-assessments-pesticides.
    A summary of the toxicological endpoints for Triflumezopyrim used
for human risk assessment is shown in the Table below.

 Summary Table of Toxicological Doses and Endpoints for Triflumezopyrim for Use in Human Health Risk Assessment
----------------------------------------------------------------------------------------------------------------
                                    Point of departure
        Exposure/scenario            and uncertainty/     RfD, PAD, LOC for     Study and toxicological effects
                                      safety factors       risk assessment
----------------------------------------------------------------------------------------------------------------
Acute dietary (All populations)..  NOAEL = 100 mg/kg/    aPAD = 1.0 mg/kg/    Acute neurotoxicity study (rats).
                                    day.                  day.                 LOAEL = 500 mg/kg/day based on
                                   UFA = 10x...........                        decreased motor activity on day
                                   UFH = 10x...........                        of dosing.
                                   FQPA SF = 1x........
----------------------------------------------------------------------------------------------------------------
Chronic dietary (All populations)  NOAEL = 17 mg/kg/day  cPAD = 0.17 mg/kg/   Combined chronic/carcinogenicity
                                   UFA = 10x...........   day.                 study (rats). LOAEL = 71/74 (M/F)
                                   UFH = 10x...........                        mg/kg/day based on decreased
                                   FQPA SF = 1x........                        absolute bodyweights in females
                                                                               and increased incidence of bile
                                                                               duct hyperplasia in males.
----------------------------------------------------------------------------------------------------------------
Cancer (Oral, dermal, inhalation)    Not likely to be carcinogenic to humans at dose levels that do not cause a
                                    significant induction in CYP2B activity. Quantification of risk using a non-
                                         linear approach (i.e., RfD) will adequately account for all chronic
                                                        toxicity, including carcinogenicity.
----------------------------------------------------------------------------------------------------------------
FQPA SF = Food Quality Protection Act Safety Factor. LOAEL = lowest-observed-adverse-effect-level. LOC = level
  of concern. mg/kg/day = milligram/kilogram/day. MOE = margin of exposure. NOAEL = no-observed-adverse-effect-
  level. PAD = population adjusted dose (a = acute, c = chronic). RfD = reference dose. UF = uncertainty factor.
  UFA = extrapolation from animal to human (interspecies). UFDB = to account for the absence of data or other
  data deficiency. UFH = potential variation in sensitivity among members of the human population
  (intraspecies). UFL = use of a LOAEL to extrapolate a NOAEL. UFS = use of a short-term study for long-term
  risk assessment.

C. Exposure Assessment

    1. Dietary exposure from food and feed uses. In evaluating dietary
exposure to triflumezopyrim, EPA considered exposure under the
petitioned-for tolerances. EPA assessed dietary exposures from
triflumezopyrim in food as follows:
    i. Acute exposure. Quantitative acute dietary exposure and risk
assessments are performed for a food-use pesticide if a toxicological
study has indicated the possibility of an effect of concern occurring
as a result of a 1-day or single exposure.
    Such effects were identified for triflumezopyrim. In estimating
acute dietary exposure, EPA used food

consumption information from the United States Department of
Agriculture (USDA) 2003-2008 National Health and Nutrition Examination
Survey, What We Eat In America (NHANES/WWEIA). As to residue levels in
food, EPA used an unrefined dietary analysis and incorporated
tolerance-level residues and assumed 100% of all rice was treated.
    ii. Chronic exposure. In conducting the chronic dietary exposure
assessment EPA used the food consumption data from the USDA 2003-2008
National Health and Nutrition Examination Survey, What We Eat In
America (NHANES/WWEIA). As to residue levels in food, EPA used an
unrefined dietary analysis and incorporated tolerance-level residues
and assumed 100% of all rice was treated.
    iii. Cancer. Based on the data summarized in Unit III.A., EPA has
concluded that triflumezopyrim is not likely to cause cancer to humans
at dose levels that do not cause a significant increase in CYP2B
activity. Additionally, there is no chronic risk from exposure to
triflumezopyrim and the chronic reference dose is protective of
potential carcinogenicity. Therefore, a dietary exposure assessment for
the purpose of assessing cancer risk is unnecessary.
    iv. Anticipated residue and percent crop treated (PCT) information.
EPA did not use anticipated residue and/or PCT information in the
dietary assessment for triflumezopyrim. Tolerance-level residues and/or
100% CT were assumed for all food commodities.
    2. Dietary exposure from drinking water. Because there are no
domestic registrations for triflumezopyrim in the United States,
dietary exposure (acute and chronic) from imported commodities is the
only source of exposure assessed. Residues from imported commodities
are not expected to reach drinking water sources.
    3. From non-dietary exposure. The term ``residential exposure'' is
used in this document to refer to non-occupational, non-dietary
exposure (e.g., for lawn and garden pest control, indoor pest control,
termiticides, and flea and tick control on pets). Triflumezopyrim is
not registered for any specific use patterns that would result in
residential exposure.
    4. Cumulative effects from substances with a common mechanism of
toxicity. Section 408(b)(2)(D)(v) of FFDCA requires that, when
considering whether to establish, modify, or revoke a tolerance, the
Agency consider ``available information'' concerning the cumulative
effects of a particular pesticide's residues and ``other substances
that have a common mechanism of toxicity.''
    EPA has not found triflumezopyrim to share a common mechanism of
toxicity with any other substances, and triflumezopyrim does not appear
to produce a toxic metabolite produced by other substances. For the
purposes of this tolerance action, therefore, EPA has assumed that
triflumezopyrim does not have a common mechanism of toxicity with other
substances. For information regarding EPA's efforts to determine which
chemicals have a common mechanism of toxicity and to evaluate the
cumulative effects of such chemicals, see EPA's Web site at http://www.epa.gov/pesticides/cumulative.

D. Safety Factor for Infants and Children

    1. In general. Section 408(b)(2)(C) of FFDCA provides that EPA
shall apply an additional tenfold (10X) margin of safety for infants
and children in the case of threshold effects to account for prenatal
and postnatal toxicity and the completeness of the database on toxicity
and exposure unless EPA determines based on reliable data that a
different margin of safety will be safe for infants and children. This
additional margin of safety is commonly referred to as the FQPA Safety
Factor (SF). In applying this provision, EPA either retains the default
value of 10X, or uses a different additional safety factor when
reliable data available to EPA support the choice of a different
factor.
    2. Prenatal and postnatal sensitivity. There was no evidence of
increased susceptibility in the rabbit developmental or the rat
reproduction toxicity studies; however, there was evidence of increased
quantitative susceptibility in the rat developmental study in rats
where an increased incidence of incomplete ossification of the parietal
skull was seen in the absence of maternal toxicity. Concern is low
since: (1) The effect is well-characterized with clearly established
NOAEL/LOAEL values; and (2) the selected endpoints for this chemical
are protective of these effects.
    3. Conclusion. EPA has determined that reliable data show the
safety of infants and children would be adequately protected if the
FQPA SF were reduced to 1X for assessing risks for all populations.
That decision is based on the following findings:
    i. The toxicity database for triflumezopyrim is complete.
    ii. Although there is evidence of neurotoxicity in the ACN study in
rats and 28-day oral toxicity study in dogs for triflumezopyrim, the
concern is low since: (1) The effects are well-characterized with
clearly established NOAEL/LOAEL values; (2) no additional neurotoxic
effects were seen in the toxicological database including the SCN; (3)
there were no corroborating neuropathological findings; (4) the
neurobehavioral signs in the dog were not observed in studies of longer
durations in dogs; and (5) the selected endpoints for this chemical are
protective of these effects. As a result, there is no need to require a
developmental neurotoxicity study or retain the 10X to account for
potential neurotoxic effects.
    iii. Although there was evidence of increased quantitative
susceptibility in the rat developmental toxicity study where incomplete
ossification of the parietal skull in the fetuses of dams treated with
a relatively high dose (200 mg/kg/day) was observed in the absence of
any maternal toxicity, concern is low since: (1) The effect is well-
characterized with clearly established NOAEL/LOAEL values and (2) the
selected endpoints for this chemical are protective of these effects.
There was no evidence of increased susceptibility in the rabbit
developmental or the rat reproduction toxicity studies.
    iv. There are no residual uncertainties identified in the exposure
databases. The dietary food exposure assessments were performed based
on considering that 100% of all rice was treated and using tolerance-
level residues. Since the metabolites were found at insignificant
levels in the metabolism studies, triflumezopyrim is considered the
only residue of concern. These assessments will not underestimate the
exposure and risks posed by triflumezopyrim.

E. Aggregate Risks and Determination of Safety

    EPA determines whether acute and chronic dietary pesticide
exposures are safe by comparing aggregate exposure estimates to the
acute PAD (aPAD) and chronic PAD (cPAD). For linear cancer risks, EPA
calculates the lifetime probability of acquiring cancer given the
estimated aggregate exposure. Short-, intermediate-, and chronic-term
risks are evaluated by comparing the estimated aggregate food, water,
and residential exposure to the appropriate PODs to ensure that an
adequate MOE exists.
    1. Acute risk. Using the exposure assumptions discussed in this
unit for acute exposure, the acute dietary exposure from food and water
to triflumezopyrim will occupy <1% of the aPAD for all infants <1 year
old, the population group receiving the greatest exposure.

    2. Chronic risk. Using the exposure assumptions described in this
unit for chronic exposure, EPA has concluded that chronic exposure to
triflumezopyrim from food will utilize <1% of the cPAD for all infants
<1 year old, the population group receiving the greatest exposure.
There are no residential uses for triflumezopyrim.
    3. Short-term and Intermediate-term risk. Triflumezopyrim is not
registered for any use patterns that would result in short-term or
intermediate-term residential exposure. Because there are no
residential uses for triflumezopyrim, as a result, aggregate risk
estimates for short- and intermediate-term exposure are equivalent to
the chronic dietary risk estimates and are not of concern.
    4. Aggregate cancer risk for U.S. population. As discussed in Unit
III.A., EPA has determined that triflumezopyrim is not likely to be
carcinogenic to humans at doses that do not cause a significant
induction in CYP2B activity. Because there is no chronic risk from
exposure to triflumezopyrim and the chronic reference dose is
protective of potential carcinogenicity, triflumezopyrim is not
expected to pose a cancer risk.
    5. Determination of safety. Based on these risk assessments, EPA
concludes that there is a reasonable certainty that no harm will result
to the general population, or to infants and children from aggregate
exposure to triflumezopyrim residues.

IV. Other Considerations

A. Analytical Enforcement Methodology

    Adequate enforcement methodology (DuPont Liquid chromatography Mass
spectrometry/mass spectrometry (LC/MS/MS) methods 36348 and 45170) is
available to enforce the tolerance expression. The method may be
requested from: Chief, Analytical Chemistry Branch, Environmental
Science Center, 701 Mapes Rd., Ft. Meade, MD 20755-5350; telephone
number:<PHONE_NUMBER>; email address<EMAIL_ADDRESS>
B. International Residue Limits

    In making its tolerance decisions, EPA seeks to harmonize U.S.
tolerances with international standards whenever possible, consistent
with U.S. food safety standards and agricultural practices. EPA
considers the international maximum residue limits (MRLs) established
by the Codex Alimentarius Commission (Codex), as required by FFDCA
section 408(b)(4). The Codex Alimentarius is a joint United Nations
Food and Agriculture Organization/World Health Organization food
standards program, and it is recognized as an international food safety
standards-setting organization in trade agreements to which the United
States is a party. EPA may establish a tolerance that is different from
a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain
the reasons for departing from the Codex level.
    The Codex has not established a MRL for triflumezopyrim.

C. Revisions to Petitioned-For Tolerances

    EPA is establishing a tolerance for rice, grain at 0.40 ppm, rather
than at 0.20 ppm as requested, in addition to establishing a tolerance
for rice, hulls of 1.0 ppm. The rice grain tolerance is based on the
OECD tolerance calculation procedure with the inputted residues
adjusted proportionally to reflect the maximum application rate. The
raw agricultural commodity of ``rice, grain'' consists of the rice
kernel, as well as the rice hull. The rice hull is considered a
processed commodity for rice, and where residues concentrate in
processed commodities, a higher tolerance to cover those residues is
warranted. Because the available data indicates a higher level of
residues on the rice hull, EPA is establishing a separate tolerance to
cover those residues.

V. Conclusion

    Therefore, tolerances are established for residues of
triflumezopyrim, (2,4-dioco-1-(5-pyrimidinylmethyl)-3-[3-
(trifluoromethyl)phenyl]-2H-pyrido[1,2-a]pyrimidinium inner salt), in
or on rice, grain at 0.40 and rice, hulls at 1.0 ppm.

VI. Statutory and Executive Order Reviews

    This action establishes tolerances under FFDCA section 408(d) in
response to a petition submitted to the Agency. The Office of
Management and Budget (OMB) has exempted these types of actions from
review under Executive Order 12866, entitled ``Regulatory Planning and
Review'' (58 FR 51735, October 4, 1993). Because this action has been
exempted from review under Executive Order 12866, this action is not
subject to Executive Order 13211, entitled ``Actions Concerning
Regulations That Significantly Affect Energy Supply, Distribution, or
Use'' (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled
``Protection of Children from Environmental Health Risks and Safety
Risks'' (62 FR 19885, April 23, 1997). This action does not contain any
information collections subject to OMB approval under the Paperwork
Reduction Act (PRA) (44 U.S.C. 3501 et seq.), nor does it require any
special considerations under Executive Order 12898, entitled ``Federal
Actions to Address Environmental Justice in Minority Populations and
Low-Income Populations'' (59 FR 7629, February 16, 1994).
    Since tolerances and exemptions that are established on the basis
of a petition under FFDCA section 408(d), such as the tolerance in this
final rule, do not require the issuance of a proposed rule, the
requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et
seq.), do not apply.
    This action directly regulates growers, food processors, food
handlers, and food retailers, not States or tribes, nor does this
action alter the relationships or distribution of power and
responsibilities established by Congress in the preemption provisions
of FFDCA section 408(n)(4). As such, the Agency has determined that
this action will not have a substantial direct effect on States or
tribal governments, on the relationship between the national government
and the States or tribal governments, or on the distribution of power
and responsibilities among the various levels of government or between
the Federal Government and Indian tribes. Thus, the Agency has
determined that Executive Order 13132, entitled ``Federalism'' (64 FR
43255, August 10, 1999) and Executive Order 13175, entitled
``Consultation and Coordination with Indian Tribal Governments'' (65 FR
67249, November 9, 2000) do not apply to this action. In addition, this
action does not impose any enforceable duty or contain any unfunded
mandate as described under Title II of the Unfunded Mandates Reform Act
(UMRA) (2 U.S.C. 1501 et seq.).
    This action does not involve any technical standards that would
require Agency consideration of voluntary consensus standards pursuant
to section 12(d) of the National Technology Transfer and Advancement
Act (NTTAA) (15 U.S.C. 272 note).

VII. Congressional Review Act

    Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.),
EPA will submit a report containing this rule and other required
information to the U.S. Senate, the U.S. House of Representatives, and
the Comptroller General of the United States prior to publication of
the rule in the Federal Register. This action is not a ``major rule''
as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

    Environmental protection, Administrative practice and procedure,
Agricultural commodities, Pesticides and pests, Reporting and
recordkeeping requirements.

    Dated: September 7, 2017.
Richard P. Keigwin, Jr.,
Director, Office of Pesticide Programs.

    Therefore, 40 CFR chapter I is amended as follows:

PART 180--[AMENDED]

0
1. The authority citation for part 180 continues to read as follows:

    Authority: 21 U.S.C. 321(q), 346a and 371.

0
2. Add Sec.  180.107 to subpart C to read as follows:

Sec.  [emsp14]180.107  Triflumezopyrim; tolerance for residues.

    (a) General. Tolerances are established for residues of the
insecticide triflumezopyrim, including its metabolites and degradates,
in or on the following food commodities in the table below. Compliance
with the tolerance levels specified below is to be determined by
measuring only triflumezopyrim (2,4-dioxo-1-(5-pyrimidinylmethyl)-3-[3-
(trifluoromethyl)phenyl]-2H-pyrido[1,2-a] pyrimidinium inner salt) in
or on the commodity.

------------------------------------------------------------------------
                                                             Parts per
                        Commodity                             million
------------------------------------------------------------------------
Rice, grain *...........................................            0.40
Rice, hulls *...........................................             1.0
------------------------------------------------------------------------
* There are no U.S. registrations for the use of triflumezopyrim on
  these commodities.

    (b) Section 18 emergency exemptions. [Reserved]
    (c) Tolerances with regional registrations. [Reserved]
    (d) Indirect or inadvertent residues. [Reserved]

[FR Doc. 2017-22356 Filed 10-13-17; 8:45 am]
 BILLING CODE 6560-50-P